GlycoNex Incorporation (TPEX:4168)
26.20
0.00 (0.00%)
Jun 3, 2026, 1:30 PM CST
GlycoNex Incorporation Revenue
GlycoNex Incorporation had revenue of 12.05M TWD in the quarter ending March 31, 2026, a decrease of -11.17%. This brings the company's revenue in the last twelve months to 36.35M, up 90.97% year-over-year. In the year 2025, GlycoNex Incorporation had annual revenue of 37.86M with 157.54% growth.
Revenue (ttm)
36.35M
Revenue Growth
+90.97%
P/S Ratio
81.11
Revenue / Employee
n/a
Employees
n/a
Market Cap
2.95B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 37.86M | 23.16M | 157.54% |
| Dec 31, 2024 | 14.70M | 12.16M | 478.32% |
| Dec 31, 2023 | 2.54M | -27.54M | -91.55% |
| Dec 31, 2022 | 30.09M | 24.61M | 449.50% |
| Dec 31, 2021 | 5.48M | 5.02M | 1,113.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Syngen Biotech | 2.07B |
| Apex Biotechnology | 1.91B |
| SYN-TECH Chem. & Pharm. | 1.26B |
| Chunghwa Chemical Synthesis & Biotech | 973.15M |
| Genovate Biotechnology | 471.48M |
| HeXun Biosciences | 293.23M |
| BioGend Therapeutics | 229.81M |
| Intech Biopharm | 117.49M |